Form 4: Aligos Therapeutics Executive Julian A. Symons Reports Stock Option Grant

Julian A. Symons, Executive Vice President and Chief Scientific Officer of Aligos Therapeutics, reported the grant of a stock option to purchase 21,693 shares of common stock on February 28, 2025.

Summary

• On February 28, 2025, Julian A. Symons, Executive Vice President and Chief Scientific Officer of Aligos Therapeutics, Inc., was granted a stock option.
• The option allows Symons to purchase 21,693 shares of Aligos Therapeutics' common stock at an exercise price of $16.87 per share.
• The options vest in equal monthly installments over four years, starting from February 28, 2025, and will be fully vested by the fourth anniversary, contingent upon continued service.
• The option expires on February 28, 2035.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine disclosure of a stock option grant, which is a standard practice in executive compensation.

Positives

• The stock option grant aligns the executive's interests with those of the shareholders, incentivizing long-term value creation.
• The vesting schedule encourages continued service and commitment from the executive.

Industry Context

Stock options are a common form of executive compensation in the biotechnology industry, used to attract and retain talent and align their interests with those of shareholders. The vesting schedule is typical for such grants.

Comparison to Industry Standards

• Stock option grants are a standard component of executive compensation packages in the biotech industry.
• Vesting schedules of four years with monthly installments are common among comparable companies.
• The number of shares granted and the exercise price would be evaluated in comparison to grants made to executives with similar roles at peer companies of similar market capitalization.

Stakeholder Impact

• Shareholders may view the stock option grant as a positive incentive for the executive to drive long-term value.
• Employees may see the grant as a sign of the company's commitment to its leadership team.

Key Dates